L-spar 10000 IU/vial IM/IV Injection
L-spar 10000 IU/vial IM/IV Injection Uses, Dosage, Side Effects, Food Interaction and all others data.
| Trade Name | L-spar 10000 IU/vial IM/IV Injection |
| Generic | L-Asparginase |
| Weight | 10000 IU/vial |
| Type | IM/IV Injection |
| Therapeutic Class | Cytotoxic Chemotherapy |
| Manufacturer | Beacon Pharmaceuticals PLC |
| Available Country | Bangladesh |
| Last Updated: | September 24, 2024 at 5:38 am |
Uses
L-spar 10000 IU/vial IM/IV Injection for Injection is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL).Dosage
L-spar 10000 IU/vial IM/IV Injection dosage
This drug may have toxic properties and must be handled and administered with care. Special handling procedures should be reviewed prior to handling and followed diligently during reconstitution and administration. Inhalation of dust or aerosols and contact with skin or mucous membranes, especially those of the eyes, must be avoided.As a component of selected multiple-agent induction regimens, L-spar 10000 IU/vial IM/IV Injection may be administered by either the intravenous or the intramuscular route. When administered intravenously this enzyme should be given over a period of not less than thirty minutes through the side arm of an already running infusion of sodium chloride injection or dextrose injection 5%. L-spar 10000 IU/vial IM/IV Injection has little tendency to cause phlebitis when given intravenously. Anaphylactic reactions require the immediate use of epinephrine, oxygen and intravenous steroids. When administering L-Asparaginase intramuscularly, the volume at a single injection site should be limited to 2ml. If a volume greater than 2ml Is to be administered, two Injection sites should be used. Unfavorable interactions of L-spar 10000 IU/vial IM/IV Injection with some antitumor agents have been demonstrated. It is recommended, therefore, that L-spar 10000 IU/vial IM/IV Injection be used in combination regimens only by physicians familiar with the benefits and risks of a given regimen. During the period of its inhibition of protein synthesis and cell replication, L-Asparaginase may interfere with the enzymatic detoxification of other drugs, particularly in the liver.Geriatric Use: Clinical studies of L-spar 10000 IU/vial IM/IV Injection did not include sufficient numbers of subjects aged 65 and olderto determine whether they respond differently from younger subjects.Side Effects
The following serious adverse reactions occur with L-spar 10000 IU/vial IM/IV Injection treatment: Anaphylaxis and serious allergic reactions Serious thrombosis Pancreatitis Glucose intolerance Coagulopathy Hepatotoxicityandabnonnal liver function The most common adverse reactions with L-spar 10000 IU/vial IM/IV Injection are allergic reactions (including anaphylaxis), hyperglycemia, pancreatitis, central nervous system (CNS) thrombosis, coagulopathy, hyperbilirubinemia, and elevated transaminases.Precaution
L-spar 10000 IU/vial IM/IV Injection for Injection is supplied in flint glass vials containing 5,000 I.U or 10,000 I.U of L-Asparginase as a sterile, Lyophilized powder for Injection for reconstitution.Interaction
L-spar 10000 IU/vial IM/IV Injection can diminish or abolish the effect of Methotrexate on malignant cells. Intravenous administration of L-spar 10000 IU/vial IM/IV Injection concurrently with or immediately before a course of Vincristine and Prednisolone may elicit increased toxicity.Drug/laboratory Test Interaction: L-spar 10000 IU/vial IM/IV Injection has been reported to interfere with the interpretation of thyroid function tests by producing a rapid and marked reduction in serum concentrations of thyroxine-binding globulin within two days after the first dose. Serum concentrations of thyroxine-binding globulin returned to pretreatment values within four weeks of the last dose of L-Asparglnase.Pregnancy & Breastfeeding use
Pregnancy Category C. In mice and rats L-spar 10000 IU/vial IM/IV Injection has been shown to retard the weight gain of mothers and fetuses when given in doses of more than 1000 International Units/kg (approximately equivalent to the recommended human dose, when adjusted for total body surface area). Resorptions, gross abnormalities and skeletal abnormalities were observed. The intravenous administration of 50 or 100 International Units/kg (approximately equivalent to 10 to 20% of the recommended human dose, when adjusted for total body surface area) to pregnant rabbits on days 8 and 9 of gestation resulted in dose-dependent embryotoxicity and gross abnormalities. There are no adequate and well-controlled studies in pregnant women. L-spar 10000 IU/vial IM/IV Injection should be given to a pregnant woman only if clearly needed.Nursing Mothers: It is not known whether L-spar 10000 IU/vial IM/IV Injection is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from L-spar 10000 IU/vial IM/IV Injection, a decision should be made to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.Storage Condition
Keep vials refrigerated at 2-8°C. Protect from light. Do not freeze. L-spar 10000 IU/vial IM/IV Injection for Injection does not contain a preservative. Store unused, reconstituted solution at 2-8°C and discard after eight hours or sooner if it becomes cloudy.Innovators Monograph
You find simplified version here L-spar 10000 IU/vial IM/IV Injection
